EBS – Emergent BioSolutions Inc.
Emergent BioSolutions Inc.EBS
$9.88Name : Emergent BioSolutions Inc.
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $535,339,904.00
EPSttm : -3.91
Emergent BioSolutions Inc.
$9.88
0.90%$0.09Float Short %
13.52
Margin Of Safety %
-18
Put/Call OI Ratio
0.24
EPS Next Q Diff
-0.23
EPS Last/This Y
13.85
EPS This/Next Y
3.07
Price
9.87
Target Price
14.33
Analyst Recom
2
Performance Q
7.86
Relative Volume
0.69
Beta
1.6
Ticker: EBS
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2024-12-19 | EBS | 8.06 | 0.36 | 0.28 | 26243 |
| 2024-12-20 | EBS | 8.09 | 0.35 | 0.39 | 26162 |
| 2024-12-23 | EBS | 8.14 | 0.21 | 0.20 | 10946 |
| 2024-12-24 | EBS | 8.3 | 0.21 | 1.18 | 11360 |
| 2024-12-26 | EBS | 8.43 | 0.23 | 0.16 | 11698 |
| 2024-12-27 | EBS | 8.26 | 0.23 | 0.32 | 11887 |
| 2024-12-30 | EBS | 9.25 | 0.24 | 0.40 | 11609 |
| 2024-12-31 | EBS | 9.55 | 0.24 | 0.27 | 12349 |
| 2025-01-02 | EBS | 10.26 | 0.25 | 0.00 | 13131 |
| 2025-01-03 | EBS | 10.31 | 0.24 | 0.24 | 13864 |
| 2025-01-06 | EBS | 10.31 | 0.24 | 0.58 | 14197 |
| 2025-01-07 | EBS | 10.29 | 0.24 | 0.17 | 14424 |
| 2025-01-08 | EBS | 10.06 | 0.24 | 0.04 | 14611 |
| 2025-01-09 | EBS | 10.09 | 0.24 | 0.04 | 14611 |
| 2025-01-10 | EBS | 9.88 | 0.24 | 0.33 | 14565 |
| 2025-01-13 | EBS | 9.4 | 0.23 | 2.26 | 13704 |
| 2025-01-14 | EBS | 9.35 | 0.23 | 0.45 | 13838 |
| 2025-01-15 | EBS | 9.52 | 0.24 | 0.14 | 13979 |
| 2025-01-16 | EBS | 9.98 | 0.24 | 0.17 | 14042 |
| 2025-01-17 | EBS | 9.89 | 0.24 | 0.08 | 14209 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2024-12-19 | EBS | 8.06 | 16.9 | - | -1.00 |
| 2024-12-20 | EBS | 8.09 | 16.9 | - | -1.00 |
| 2024-12-23 | EBS | 8.15 | 16.9 | - | -1.00 |
| 2024-12-24 | EBS | 8.30 | 16.9 | - | -1.00 |
| 2024-12-26 | EBS | 8.42 | 16.9 | - | -1.00 |
| 2024-12-27 | EBS | 8.28 | 16.9 | - | -1.00 |
| 2024-12-30 | EBS | 9.24 | 16.9 | - | -1.00 |
| 2024-12-31 | EBS | 9.57 | 16.9 | - | -1.00 |
| 2025-01-02 | EBS | 10.24 | 16.9 | 253.4 | -1.00 |
| 2025-01-03 | EBS | 10.31 | 16.9 | 248.0 | -1.00 |
| 2025-01-06 | EBS | 10.29 | 16.9 | 247.5 | -1.00 |
| 2025-01-07 | EBS | 10.27 | 16.9 | 247.5 | -1.00 |
| 2025-01-08 | EBS | 10.09 | 16.9 | 246.3 | -1.00 |
| 2025-01-09 | EBS | 10.09 | 16.9 | 247.7 | -1.00 |
| 2025-01-10 | EBS | 9.86 | 16.9 | 245.9 | -1.00 |
| 2025-01-13 | EBS | 9.40 | 16.9 | 243.9 | -1.00 |
| 2025-01-14 | EBS | 9.34 | 16.9 | 247.1 | -1.00 |
| 2025-01-15 | EBS | 9.51 | 16.9 | 249.0 | -1.00 |
| 2025-01-16 | EBS | 9.97 | 16.9 | 251.4 | -1.00 |
| 2025-01-17 | EBS | 9.87 | 16.9 | 247.0 | -1.00 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2024-12-19 | EBS | -1.80 | 3.27 | 13.31 |
| 2024-12-20 | EBS | -1.80 | 3.27 | 13.31 |
| 2024-12-23 | EBS | -1.77 | 3.38 | 13.32 |
| 2024-12-24 | EBS | -1.77 | 3.38 | 13.30 |
| 2024-12-26 | EBS | -1.80 | 3.38 | 13.32 |
| 2024-12-27 | EBS | -1.83 | 3.38 | 13.32 |
| 2024-12-30 | EBS | -1.86 | 3.35 | 13.32 |
| 2024-12-31 | EBS | -1.86 | 3.35 | 13.32 |
| 2025-01-02 | EBS | -1.77 | 3.35 | 13.32 |
| 2025-01-03 | EBS | -1.83 | 3.35 | 13.32 |
| 2025-01-06 | EBS | -1.82 | 3.13 | 13.32 |
| 2025-01-07 | EBS | -1.82 | 3.13 | 13.32 |
| 2025-01-08 | EBS | -1.83 | 3.13 | 13.32 |
| 2025-01-09 | EBS | -2.67 | 3.13 | 13.15 |
| 2025-01-10 | EBS | -2.67 | 3.13 | 13.15 |
| 2025-01-13 | EBS | -2.67 | 3.12 | 13.52 |
| 2025-01-14 | EBS | -2.67 | 3.12 | 13.52 |
| 2025-01-15 | EBS | -2.67 | 3.12 | 13.52 |
| 2025-01-16 | EBS | -2.67 | 3.12 | 13.52 |
| 2025-01-17 | EBS | -2.67 | 3.12 | 13.52 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.37
Avg. EPS Est. Current Quarter
-0.64
Avg. EPS Est. Next Quarter
1.14
Insider Transactions
-2.67
Institutional Transactions
3.12
Beta
1.6
Average Sales Estimate Current Quarter
259
Average Sales Estimate Next Quarter
Fair Value
8.08
Quality Score
39
Growth Score
54
Sentiment Score
92
Actual DrawDown %
92.8
Max Drawdown 5-Year %
-98.9
Target Price
14.33
P/E
Forward P/E
7.69
PEG
P/S
0.48
P/B
1.05
P/Free Cash Flow
3.88
EPS
-4.1
Average EPS Est. Cur. Y
-1
EPS Next Y. (Est.)
2.07
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-18.55
Relative Volume
0.69
Return on Equity vs Sector %
-60.1
Return on Equity vs Industry %
-49.7
EPS 1 7Days Diff
0.7
EPS 1 30Days Diff
0.67
EBIT Estimation
247
Emergent BioSolutions Inc.Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 1600
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
stock quote shares EBS – Emergent BioSolutions Inc. Stock Price stock today
news today EBS – Emergent BioSolutions Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch EBS – Emergent BioSolutions Inc. yahoo finance google finance
stock history EBS – Emergent BioSolutions Inc. invest stock market
stock prices EBS premarket after hours
ticker EBS fair value insiders trading